Aug. 6, 2020: Recent trends in drug interaction rates; integrase inhibitors and cardiac event risk; a deep dive into HIV drug resistance in Florida; frailty symptoms and neurocognitive disorders amidst high CD4 counts.
The international news story that broke at AIDS 2020, explained by the lead researcher.
An interview with Andrew Hill, Ph.D., about his research presented at AIDS 2020.
July 30, 2020: HIV prevention shortfalls among adolescents of color; PrEP use among trans people; PrEP information gaps among women of color; the case for vacation-based (a.k.a. episodic) PrEP.
Richard Jefferys of Treatment Action Group discusses the pipeline for new modalities being explored for treatment, PrEP, vaccine, and cure.
July 23, 2020: Depression and HIV risk mitigation among MSM; a consistent HIV provider is good for CD4 and viral load; spirituality and HIV prevention; HCV treatment access and reinfection risk.
July 16, 2020: Starting HIV treatment during hospitalization for people who use drugs; type of substance use affects viral suppression odds; benefits of a cross-disciplinary medical support team; does STI recency dictate PrEP necessity for women?
COVID-19 or no, there was still plenty to learn at this year's virtual conference, including for U.S. clinicians seeking to improve the care and treatment they provide to their patients living with HIV.
A pair of presentations at AIDS 2020 provides some of the largest studies to date on COVID-19 among people with HIV, but leaves us with many questions about the interplay between the two viruses.
July 9, 2020: Abysmal HIV testing rates in U.S. ambulatory care settings; STI testing frequency in PrEP users; trends in U.S. PrEP uptake; integrating opioid therapy with HCV care in people who inject drugs.